197 related articles for article (PubMed ID: 21677636)
1. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome.
Strobel S; Abarrategui-Garrido C; Fariza-Requejo E; Seeberger H; Sánchez-Corral P; Józsi M
Kidney Int; 2011 Aug; 80(4):397-404. PubMed ID: 21677636
[TBL] [Abstract][Full Text] [Related]
2. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome.
Hofer J; Janecke AR; Zimmerhackl LB; Riedl M; Rosales A; Giner T; Cortina G; Haindl CJ; Petzelberger B; Pawlik M; Jeller V; Vester U; Gadner B; van Husen M; Moritz ML; Würzner R; Jungraithmayr T;
Clin J Am Soc Nephrol; 2013 Mar; 8(3):407-15. PubMed ID: 23243267
[TBL] [Abstract][Full Text] [Related]
3. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome.
Moore I; Strain L; Pappworth I; Kavanagh D; Barlow PN; Herbert AP; Schmidt CQ; Staniforth SJ; Holmes LV; Ward R; Morgan L; Goodship TH; Marchbank KJ
Blood; 2010 Jan; 115(2):379-87. PubMed ID: 19861685
[TBL] [Abstract][Full Text] [Related]
4. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome.
Abarrategui-Garrido C; Martínez-Barricarte R; López-Trascasa M; de Córdoba SR; Sánchez-Corral P
Blood; 2009 Nov; 114(19):4261-71. PubMed ID: 19745068
[TBL] [Abstract][Full Text] [Related]
5. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.
Bhattacharjee A; Reuter S; Trojnár E; Kolodziejczyk R; Seeberger H; Hyvärinen S; Uzonyi B; Szilágyi Á; Prohászka Z; Goldman A; Józsi M; Jokiranta TS
J Biol Chem; 2015 Apr; 290(15):9500-10. PubMed ID: 25659429
[TBL] [Abstract][Full Text] [Related]
6. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1/CFHR3 deficiency.
Lee BH; Kwak SH; Shin JI; Lee SH; Choi HJ; Kang HG; Ha IS; Lee JS; Dragon-Durey MA; Choi Y; Cheong HI
Pediatr Res; 2009 Sep; 66(3):336-40. PubMed ID: 19531976
[TBL] [Abstract][Full Text] [Related]
7. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency.
Józsi M; Licht C; Strobel S; Zipfel SL; Richter H; Heinen S; Zipfel PF; Skerka C
Blood; 2008 Feb; 111(3):1512-4. PubMed ID: 18006700
[TBL] [Abstract][Full Text] [Related]
8. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children.
Sinha A; Gulati A; Saini S; Blanc C; Gupta A; Gurjar BS; Saini H; Kotresh ST; Ali U; Bhatia D; Ohri A; Kumar M; Agarwal I; Gulati S; Anand K; Vijayakumar M; Sinha R; Sethi S; Salmona M; George A; Bal V; Singh G; Dinda AK; Hari P; Rath S; Dragon-Durey MA; Bagga A;
Kidney Int; 2014 May; 85(5):1151-60. PubMed ID: 24088957
[TBL] [Abstract][Full Text] [Related]
9. The autoimmune disease DEAP-hemolytic uremic syndrome.
Skerka C; Zipfel PF; Müller D; Micklisch S; Riedl M; Zimmerhackl LB; Hofer J
Semin Thromb Hemost; 2010 Sep; 36(6):625-32. PubMed ID: 20865639
[TBL] [Abstract][Full Text] [Related]
10. Autoantibodies in haemolytic uraemic syndrome (HUS).
Skerka C; Józsi M; Zipfel PF; Dragon-Durey MA; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):227-32. PubMed ID: 19190803
[TBL] [Abstract][Full Text] [Related]
11. Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
Kopp A; Strobel S; Tortajada A; Rodríguez de Córdoba S; Sánchez-Corral P; Prohászka Z; López-Trascasa M; Józsi M
J Immunol; 2012 Aug; 189(4):1858-67. PubMed ID: 22786770
[TBL] [Abstract][Full Text] [Related]
12. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor H autoantibodies.
Boyer O; Balzamo E; Charbit M; Biebuyck-Gougé N; Salomon R; Dragon-Durey MA; Frémeaux-Bacchi V; Niaudet P
Am J Kidney Dis; 2010 May; 55(5):923-7. PubMed ID: 20202729
[TBL] [Abstract][Full Text] [Related]
13. A novel hybrid CFH/CFHR3 gene generated by a microhomology-mediated deletion in familial atypical hemolytic uremic syndrome.
Francis NJ; McNicholas B; Awan A; Waldron M; Reddan D; Sadlier D; Kavanagh D; Strain L; Marchbank KJ; Harris CL; Goodship TH
Blood; 2012 Jan; 119(2):591-601. PubMed ID: 22058112
[TBL] [Abstract][Full Text] [Related]
14. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS.
Dragon-Durey MA; Blanc C; Garnier A; Hofer J; Sethi SK; Zimmerhackl LB
Semin Thromb Hemost; 2010 Sep; 36(6):633-40. PubMed ID: 20865640
[TBL] [Abstract][Full Text] [Related]
15. A novel atypical hemolytic uremic syndrome-associated hybrid CFHR1/CFH gene encoding a fusion protein that antagonizes factor H-dependent complement regulation.
Valoti E; Alberti M; Tortajada A; Garcia-Fernandez J; Gastoldi S; Besso L; Bresin E; Remuzzi G; Rodriguez de Cordoba S; Noris M
J Am Soc Nephrol; 2015 Jan; 26(1):209-19. PubMed ID: 24904082
[TBL] [Abstract][Full Text] [Related]
16. Complement factor H, FHR-3 and FHR-1 variants associate in an extended haplotype conferring increased risk of atypical hemolytic uremic syndrome.
Bernabéu-Herrero ME; Jiménez-Alcázar M; Anter J; Pinto S; Sánchez Chinchilla D; Garrido S; López-Trascasa M; Rodríguez de Córdoba S; Sánchez-Corral P
Mol Immunol; 2015 Oct; 67(2 Pt B):276-86. PubMed ID: 26163426
[TBL] [Abstract][Full Text] [Related]
17. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome.
Zipfel PF; Edey M; Heinen S; Józsi M; Richter H; Misselwitz J; Hoppe B; Routledge D; Strain L; Hughes AE; Goodship JA; Licht C; Goodship TH; Skerka C
PLoS Genet; 2007 Mar; 3(3):e41. PubMed ID: 17367211
[TBL] [Abstract][Full Text] [Related]
18. Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Grenda R; Jarmużek W; Rubik J; Prokurat S; Miklaszewska M; Drozdz D; Zachwieja K; Ardissino G; Hofer J
Pediatr Transplant; 2015 Sep; 19(6):E130-4. PubMed ID: 26087050
[TBL] [Abstract][Full Text] [Related]
19. DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome.
Zipfel PF; Mache C; Müller D; Licht C; Wigger M; Skerka C;
Pediatr Nephrol; 2010 Oct; 25(10):2009-19. PubMed ID: 20157737
[TBL] [Abstract][Full Text] [Related]
20. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases.
Blanc C; Togarsimalemath SK; Chauvet S; Le Quintrec M; Moulin B; Buchler M; Jokiranta TS; Roumenina LT; Fremeaux-Bacchi V; Dragon-Durey MA
J Immunol; 2015 Jun; 194(11):5129-38. PubMed ID: 25917093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
